Consistently, we herein identified that USP22 is drastically upregulated in A549 and H1299 cancer cells that survived cisplatin treatment (Additional file 1: Figure S5), indicating an involvement of USP22 in cisplatin resistance and DNA damage repair. The gene discussed is USP22; the disease is cancer.